• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindoles

Gallium(III) Phthalocyanine Hydroxide: A Promising Compound in Biomedical Applications

Gallium(III) phthalocyanine hydroxide, with the CAS No. 63371-84-6, is a unique coordination compound that has garnered significant attention in the field of biomedical research. This compound belongs to the class of phthalocyanines, which are macrocyclic compounds characterized by their high stability and unique electronic properties. Recent studies have highlighted its potential in various biomedical applications, including photodynamic therapy, imaging, and drug delivery systems. The structural features of Gallium(III) phthalocyanine hydroxide make it a versatile candidate for developing novel therapeutic strategies.

Gallium(III) phthalocyanine hydroxide exhibits a planar, conjugated structure that allows for efficient light absorption and energy transfer. The incorporation of gallium ions into the phthalocyanine ring enhances its photophysical properties, making it suitable for applications requiring high photostability. Recent advancements in nanotechnology have enabled the synthesis of Gallium(III) phthalocyanine hydroxide in various forms, such as nanoparticles and thin films, which can be tailored for specific biomedical purposes. These modifications have been shown to improve the compound's solubility and bioavailability, addressing some of the challenges associated with traditional phthalocyanine derivatives.

The CAS No. 63371-84-6 compound has been extensively studied for its potential in photodynamic therapy (PDT). PDT is a minimally invasive treatment that utilizes light-sensitive compounds to generate reactive oxygen species (ROS) that can destroy cancer cells. Gallium(III) phthalocyanine hydroxide has demonstrated excellent photodynamic activity against a range of cancer cell lines, including breast, lung, and prostate cancer. A 2023 study published in Advanced Materials reported that Gallium(III) phthalocyanine hydroxide nanoparticles exhibited enhanced phototoxicity compared to conventional phthalocyanine derivatives, attributed to their improved light absorption and charge transfer properties.

In addition to its role in PDT, Gallium(III) phthalocyanine hydroxide is being explored for its potential in biomedical imaging. The compound's strong absorption in the near-infrared (NIR) region makes it an attractive candidate for optical imaging applications. A recent study published in ACS Nano demonstrated that Gallium(III) phthalocyanine hydroxide could be used as a contrast agent for in vivo imaging, providing high-resolution images of tumor tissues. The ability to visualize tumors in real-time could significantly enhance the accuracy of diagnostic procedures and improve treatment outcomes.

The CAS No. 63371-84-6 compound is also being investigated for its potential in drug delivery systems. Researchers have developed Gallium(III) phthalocyanine hydroxide-based nanocarriers that can deliver therapeutic agents to specific target sites. A 2024 study published in Journal of Controlled Release showed that Gallium(III) phthalocyanine hydroxide nanoparticles could be functionalized with targeting ligands, enabling site-specific drug delivery. This approach has the potential to reduce systemic toxicity and improve the efficacy of therapeutic agents.

Recent advancements in synthetic chemistry have led to the development of novel Gallium(III) phthalocyanine hydroxide derivatives with enhanced properties. For example, researchers have synthesized Gallium(III) phthalocyanine hydroxide with different metal centers, which can modulate its photophysical and biochemical properties. A 2023 study published in Chemical Communications reported that the incorporation of different gallium isotopes into the Gallium(III) phthalocyanine hydroxide structure could improve its stability and functionality for biomedical applications.

The CAS No. 63371-84-6 compound has also been studied for its potential in biosensing applications. Its unique optical properties make it suitable for developing sensors that can detect biomolecules with high sensitivity. A recent study published in Biosensors & Bioelectronics demonstrated that Gallium(III) phthalocyanine hydroxide could be used as a fluorescent probe for detecting cancer biomarkers. This application could lead to the development of non-invasive diagnostic tools that can provide early detection of diseases.

In terms of safety, Gallium(III) phthalocyanine hydroxide has been evaluated for its biocompatibility and toxicity. Studies have shown that the compound is generally non-toxic at therapeutic concentrations, making it a promising candidate for clinical applications. However, further research is needed to fully understand its long-term effects and optimize its therapeutic potential.

The CAS No. 63371-84-6 compound represents a significant advancement in the field of biomedical materials. Its unique properties and versatile applications make it a valuable candidate for developing novel therapeutic strategies. As research continues to uncover new possibilities, the future of Gallium(III) phthalocyanine hydroxide in biomedical applications remains promising. The ongoing exploration of this compound is expected to lead to breakthroughs in cancer treatment, imaging, and drug delivery, ultimately improving patient outcomes and advancing the field of medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)